FIT Biotech is a biotechnology company focusing on research and commercialization aiming to revolutionize health care by developing safer as well as more cost-e icient and functional cures.
Innovative gene delivery technologies and DNA vaccines can be applied, inter alia, towards cancer immunotherapy, enzyme replacement in certain orphan diseases as well as the prevention and treatment of di erent infectious diseases such as HIV. All of our R&D targeted products would represent medical breakthroughs if they succeed.
FIT Biotech’s technology o ers the technological advantage of scalability as it serves as a platform for developing gene-based therapies at a faster rate. Our product development is focusing on DNA based technology free of virus unlike most operators in this sector. In addition to medical benefits, DNA based drugs also o er significant cost savings.
In November, we were granted a patent that gives us exclusive intellectual property rights in the United States to commercialize our GTU®-based DNA vaccines, including FIT-06, for the treatment of HIV patients. This is of great economic consequence since it gives us possibility to exclusive rights to commercialize our vaccine candidate at a premium price. The patent is a prerequisite for licensing the marketing rights to a major pharmaceutical company. The next step will be launching Phase 2 clinical trial with European HIV and Vaccine Alliance (EHVA). The objective of the clinical trial is to provide a safer and cost-e ective functional cure for HIV patients.
FIT Biotech o ers investors an unique opportunity to participate in the commercialization of drug candidates based on own patents. While drug development is a long-term process and high-risk venture, there should be multiple milestones met along the way although early stage licensing agreements are increasingly common.
Our business model is based on licensing our drug candidates to corporate partners who develop them further and introduce drugs on the market. We have multiple drug development projects as well as collaborative projects with inter- national biotech companies, pharmaceutical companies and academic research institutions.
I started as the CEO of FIT Biotech in January 2018 a er serving 16 years as a member of the Board. I am particularly proud of our dedicated top-team with long experience and expertise in the international biotechnical business. With this team and our unique, proprietary technology platform we pursue a role as a leading and recognized European biotechnical company in the field of biotechnology.”
FIT Biotech Oy